228260-15-9Relevant academic research and scientific papers
Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry
Guilinger, John P.,Archna, Archna,Augustin, Martin,Bergmann, Andreas,Centrella, Paolo A.,Clark, Matthew A.,Cuozzo, John W.,D?ther, Maike,Guié, Marie-Aude,Habeshian, Sevan,Kiefersauer, Reiner,Krapp, Stephan,Lammens, Alfred,Lercher, Lukas,Liu, Julie,Liu, Yanbin,Maskos, Klaus,Mrosek, Michael,Pflügler, Klaus,Siegert, Markus,Thomson, Heather A.,Tian, Xia,Zhang, Ying,Konz Makino, Debora L.,Keefe, Anthony D.
, (2021)
Libraries of DNA-Encoded small molecules created using combinatorial chemistry and synthetic oligonucleotides are being applied to drug discovery projects across the pharmaceutical industry. The majority of reported projects describe the discovery of reve
Design, synthesis, and evaluation of a novel benzamidine-based inhibitor of VEGF-C binding to Neuropilin-2
Parker, Matthew W.,Said, Ahmed M.,Vander Kooi, Craig W.
supporting information, (2020/04/28)
The Neuropilin (Nrp) family of cell surface receptors have key physiological and pathological functions. Nrp2 is of particular interest due to its involvement in tumor metastasis. Currently, peptide and small molecule inhibitors that target Nrp utilize ar
COVALENT BTK INHIBITORS AND USES THEREOF
-
Page/Page column 26, (2017/12/15)
The present invention features compounds having BTK inhibitory activity. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions, such as cardiova
